# Aevius

> Mass General Brigham spinout building longitudinal patient-data foundation models for health systems, payers and life-sciences companies.

## Why it is interesting

An Insight Partners-led $22M company financing announced Nov 17 2026 addresses multimodal patient data, but its original issuer release does not identify a round series, valuation, clinical-validation study or paying customers.

## Profile

- **Latest funding:** Financing (series undisclosed by issuer) — $22M (November 17, 2026)
- **Latest known valuation:** Undisclosed (November 17, 2026)
- **Total disclosed equity funding:** $22M
- **Stage:** N/A
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-19
- **Latest funding investors:** Insight Partners

## Key facts

- Company-issued Nov 17 2026: $22M funding led by Insight Partners, formal round series not issuer-confirmed.
- Mass General Brigham spinout; founders previously built Modella AI, acquired by AstraZeneca for an undisclosed amount.
- A proposed reusable patient representation across time, notes, imaging and medical records, not an approved diagnostic.
- No external predictive benchmarks, deployed customer list, clinical endpoint validation, pricing or audited revenue provided.

## Funding history

- Financing (series undisclosed by issuer) · $22M · November 17, 2026
  Source: https://www.businesswire.com/news/home/20261117488744/en/

## Investors in our directory

- https://venturecapitaltracker.com/fund/insight-partners

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 19, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/aevius-clinical-intelligence
